295 results about "Guinea pig" patented technology

The invention provides a SARS-CoV-2 vaccine using human type-5 replication-defective adenovirus as a vector. The vaccine uses E1 and E3 to be combined with replication-defective human type-5 adenovirus as the vector and HEK293 cells integrating adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is the 2019 SARS-CoV-2 S protein gene (Ad5-nCoV) which is subjected to optimization design. After the S protein gene is optimized, the expression level in transfected cells is increased significantly. The vaccine has good immunogenicity in mouse and guinea pig models, andcan induce a body to produce a strong cellular and humoral immune response in a short time. Studies on the protective effect of hACE2 transgenic mice show that after 14 days of single immunization ofAd5-nCoV, the viral load in lung tissue can be significantly reduced, and it is indicated that the vaccine has a good immunoprotective effect on the 2019 SARS-CoV-2. In addition, the vaccine is quick, simple and convenient to prepare, and can be mass-produced in a short period of time to respond to sudden outbreaks.

The invention relates to a reagent kit and a detecting method for using loop-mediated isothermal amplification (LAMP) technique to detect aeromonas caviae, which belongs to the pathogen diagnosis field. The main technical scheme of the invention comprises: utilizing the LAMP technique, designing four pairs of high specificity primers aiming at six zones of 16s and 23s ribosome RNA gene transcription spacer region, and achieving the purpose for detecting the aeromonas caviae with specificity. Compared with a traditional method, equipment and operational steps which are needed in the method are simple, the method has the advantages of rapidness and high specificity, and the detecting cost is lower, which is suitable for common clinics and field detections.

The invention discloses an Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and a preparation method thereof. The recombinant vaccine comprises the following components: proteins coded by foot-and-mouth disease virus multi-epitope genes and the fusion genes of carrier proteins, and foot-and-mouth disease virus 3D proteins. The preparation method comprises the following steps: diluting the proteins expressed by the foot-and-mouth disease virus multi-epitope genes and the fusion genes of the carrier proteins and the foot-and-mouth disease virus 3D proteins, mixing the diluted proteins uniformly, adding an adjuvant into the mixture to emulsify the mixture. Animal models and animal immune effect experiments show that the bovine Asia1 epitope recombinant vaccine can make comprehensive immune protective response, can induce injected and immunized bovine and guinea pigs to generate high level neutralizing antibodies, and can also induce cell immune response, so the recombinant vaccine can effectively protect animals against the virulent attack of the foot-and-mouth disease viruses.

The invention provides a fluorescent probe of reversible sulfur dioxide/sulphurous acid (hydrogen) salt, with the chemical name of 7-diethylin-2-(9-ethyl-9H-carbazole-3) benzo iso-pyran oxonium ion. The fluorescent probe can detect sulfur dioxide/sulphurous acid (hydrogen) salt in a solution, cells, tissues or a living body, wherein the living body includes fish, mice, rat, guinea pig and rabbit;and reversibility is realized by formaldehyde. The fluorescent probe is simple in synthesis steps, easily available in material, high in yield and suitable for industrial application.

The invention discloses an ELISA agent box to test Asial foot-and-mouth disease virus and making method of the agent box, which comprises the following parts: solid support to connect the detected sample, mono-clone antibody to clad Asial foot-and-mouth disease virus on the solid support connected with the detected sample, multi-clone antibody of guinea pig as dianti-Asial foot-and-mouth disease virus, rabbit anti-guinea pig lgG marked by enzyme, standard serum, colorless substrate, terminal liquid.

The invention provides a compound angelica preparation, the dosage of the raw medicinal materials of which is calculated according to the weight, namely 10-30g of angelica, 5-15g of caladium and 2-8g of sophora Flavescens Ait. The preparation includes oral liquid, spray, and aerosol, dropping pill, capsule or tablet. Compared to the prior art, the preparation of the invention has remarkable effect on curing asthma, cough and expectoration, while the animal experiment also shows that the preparation has remarkable anti-inflammation and cough relieving actions on mice and has better asthma curing action on Guinea pig. Moreover, the preparation only contains three Chinese traditional medicines and is of refined formula, advanced preparation process and can be prepared to be various formulations like dropping pill, aerosol, spray, capsule and tablet and so on with easy administration. The beneficial effects of the preparation is further specified combining with the embodiment and the clinical experiment as below; the preparation can be applied in preparing drugs with actions of anti-inflammation, cough relieving and asthma curing, can also be applied in preparing drugs for treating acute and chronic bronchitis, chronic obstructive pulmonary diseases and upper respiratory tract infection respiratory diseases.

This patent application is for an apparatus to safely expose guinea pigs and other small animals to biohazardous aerosol. It is composed of three main chambers housed in an outer box which fits within a conventionally sized biosafety cabinet. The animal chamber contains a removable housing unit for four or eight guinea pigs. The aerosol chamber is separate to minimize fur contamination. The nebulizer chamber is also sealed to reduce risks from leakages. This apparatus is easily decontaminated by immersion in disinfectant. The first version of the prototype, tentatively named the AXS1, has been tested for safety, ergonomics, efficiency of rodent exposure to bacteria, airflow, access points, seal mechanisms, and size.

The invention discloses a multiple liquid phase gene chip method and a reagent for rapidly detecting guinea pig LCMV, SV, PVM and Reo-3 viruses. The operation is simple. A target amplified fragment is acquired through PCR, and then the amplified product, fluorescent coding micro-balloon and streptavidin-phycoerythrin are hybridized, MFI value is read through a tester and different viruses are distinguished. According to the method provided by the invention, the rat lymphocyte choriomeningitis virus, sendai virus, rat pneumonia virus and Reo-3 virus can be accurately detected at the same time; the specificity is strong, the sensitivity is high and the repeatability is excellent; compared with the traditional detection method, the method has the advantages that different target molecules in a same sample can be detected, the detection flux is high, the sample dosage is less, the operation is simple and quick, the detection cost is greatly reduced and the detection efficiency is increased.

The invention discloses pet dog feed, which comprises the following components in parts by weight: 400-600 parts of wheat gluten, 400-600 parts of bone powder, 400-600 parts of fish powder, 200-300 parts of corn powder, 100-200 parts of potato powder, 1-5 parts of tryptophane, 1-5 parts of phenylalanine, 1-5 parts of valine, 1-5 parts of arginine, 1-5 parts of lysine, 1-5 parts of glutamic acid, 1-5 parts of threonine and 1-5 parts of sodium chloride. The pet feed is suitable for feeding pet dogs; under proper situations, the pet feed can also be used for feeding pet cats, guinea pigs and other pets. In the formula, the wheat gluten plays a role in increasing the flexibility and the plasticity of the feed, the fish powder, the bone powder and the potato powder have abundant nutrition and contain abundant amino acids, vitamins and other essential nutrition, and the sodium chloride can supplement the content of sodium ions in pet bodies. The feed is high in nutritional value and does not contain any additives; furthermore, the preparation is simple, the cost is low and the pet dog feed is suitable for purchase and use by ordinary families.

The invention relates to an extraction method of mouse platelet. Blood drawn from orbita vein of mouse is placed into an anticoagulation centrifugal tube, centrifugated at the speed of 800rmp for 10min after standing for 30min, and the extracted supernatant fluid is plasma rich in platelet. The supernatant fluid is placed in a clean test tube and centrifugated at the speed of 3500rpm for 10min. After filtering the supernatant fluid, the sediments at the bottom of the tube are the platelets. 50ul to 100ul of ammonium oxalate solution with a mass concentration of 1 percent is added into the test tube and slightly stirred with a glass rod, and then 2ml to 3ml of ammonium oxalate solution with a mass concentration of 1 percent is added, and stood for 5min, to make sure the hematid is dissolved; the hematid is centrifugated at the speed of 3500rpm for 10min, after the supernatant fluid is abandoned, the test tube is added with a few platelet scrub solution and blown and beaten to turn the platelet into a platelet suspension. The suspension is centrifugated at the speed of 3300rpm for 10min, removed the supernatant in the suspension, the test tube is added with a few platelet scrub solution and blown and beaten to turn the platelet into a platelet suspension. The platelet is used as an antigen to immunify guinea pigs, and the serum of such guines pigs is injected into the mouse to prepare allergic purpura. The preparation method has simple operation, can obtain high concentration platelet, and can comparatively better solve the problem of impure platelet.

The invention discloses a metabonomics analysis method base on acute anaphylactic reaction. The invention mainly starts from the systems biology, and applies a UPLC-QTof/MS technology platform for UPLC and SPE-RRLC-Q-TOF combination, and establishes an acute anaphylactic reaction guinea pig serum metabonomics evaluation model, and provides a basis for further research of medicament acute anaphylactic reaction. During analysis, the UPLC and SPE-RRLC-Q-TOF combination technology is used for detecting serum samples of normal guinea pig and experiment guinea pig with acute anaphylactic reaction generated by induction, and a metabolome spectrogram is obtained by an acquisition method after optimization, and a mode identification method suitable for evaluating animal acute anaphylactic reaction is established for analyzing the metabolome data, which establishes a base for subsequently and furtherly screening biological tag with characteristics and developing a new animal acute anaphylactic reaction detection method.

Systems and methods are effective in electrically grounding animals that are kept indoors, such as pets (dogs, cats, hamsters, iguanas, fish, birds, etc.), lab caged animals used for clinical trials (guinea pigs, rats, etc.). The inventive apparatus and concepts are also applicable to fish and other creatures in aquariums and animals that are kept indoors at night or during harsh weather, including livestock (cattle, sheep, pigs, lamb, etc.) and horse stables.

The invention relates to the technical field of biomedicine, and particularly provides varicella-zoster virus gB-gE-gH-gL fusion protein, a genetic engineering subunit vaccine and preparation methods. The fusion protein comprises a VZV gB extracellular region, a gE extracellular region, a gH truncated fragment and a gL truncated fragment. The amino acid sequence of encoded protein of the fusion protein is SEQ ID NO:1, and one amino acid sequence is SEQ ID NO:2. A prokaryotic expression vector is utilized for constructing escherichia coli BL21 (DE3) host bacteria capable of expressing the VZV gB-gE-gH-gL fusion protein. The fusion protein is purified and mixed with a medicinal adjuvant to be prepared into the genetic engineering subunit vaccine. Compared with a currently-used VZV attenuated live vaccine, the vaccine can induce immune mice to generate higher specific humoral immunity and cell-mediated immunity and can prevent dormant infection that VZV is spread to dorsal root ganglions and intestinal ganglions through blood flow, the safety of the VZV vaccine is effectively improved, and therefore the genetic engineering subunit vaccine is an alternative vaccine with potential clinical application value.

The Chinese medicine composition for treating intestinal irritable syndrome is prepared with gallnut, nutmeg, red ginseng, deglued antler powder, dark plum and myrobalan fruit as material and through the technological process including water extraction, extracting volatile oil, inclusion with cyclodextrin, grinding into fine powder and other steps. The pharmacological experiments show that the medicine of the present invention can inhibit the motion of small intestine, resist the sthenic motion of small intestine caused by Neostigmine, resist diarrhea caused by rhubarb, promote the absorption of water inside intestine caused by mannitol, etc. and has relatively high anti-diarrhea effect and high safety.

The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg/kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.

Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the “free” protein antigen. The 2100 coat proteins comprising the rod-shaped capsid of Tobacco mosaic virus (TMV) can accommodate short peptide insertions into the primary sequence, but the display of larger protein moieties on the virion surface by genetic fusions to the capsid protein has not been possible. Since TMV lacks surface exposed residues compatible with commonly available linker chemistries, we employed a randomized library approach to introduce a reactive lysine at the externally located at the amino-terminus of the coat protein. We found that we could easily control the extent of virion conjugation and demonstrated stoichiometric biotinylation of the introduced lysine. To characterize this modular platform for the display of heterologous proteins, we bound a model antigen (streptavidin (SA)-green fluorescent protein (GFP), expressed and purified from plants) to the surface of TMV, creating a GFP-SA decorated virus particle. Rapid and quantitative determination of the level of TMV capsid decoration was accomplished by subjecting the complex to amino acid analysis and solving the family of linear equations relating the pmoles of each residue to the known amino acid composition of the complex components. We obtained a GFP-SA tetramer loading of 26%, which corresponds to display of approximately 2200 GFP moieties per intact virion. We evaluated the immunogenicity of GFP decorated virions in both mice and guinea pigs, and found augmented humoral IgG titers in both species, relative to unbound GFP-SA tetramer. In mice, we observed a detectable humoral immune response after only a single immunization with the TMV-protein complex. By demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by genetic manipulation.

The invention discloses an application of a celastrus orbiculatus alcohol extract in preparing a medicine for treating non-alcoholic fatty liver disease (NAFLD). By adopting a high-fat diet induced guinea pig NAFLD model and taking simvastatin as a positive control medicine, the celastrus orbiculatus alcohol extract is orally taken for 8 weeks, then influence of the celastrus orbiculatus alcohol extract on NAFLD is observed, and a corresponding mechanism is explored; and the result indicates that the celastrus orbiculatus alcohol extract can be used for obviously improving the high-fat induced pathological alteration of liver tissue, easing the damage of liver cells, reducing the lipid accumulation in liver and suppressing oxidative stress reaction in liver. According to the invention, a new application of the celastrus orbiculatus alcohol extract is developed, and a new means of treating NAFLD is provided.

The invention discloses a novel porcine reproductive and respiratory syndrome virus variant GP5 recombinant protein and a preparation method and application thereof. The novel porcine reproductive and respiratory syndrome virus variant GP5 recombinant protein is a soluble complete protein expressing PRRSV GP5 or soluble protein expressing PRRSV GP5 fused with TAT. A pCold 1F DNA is employed for efficient soluble expression of the PRRSV mutant GP5 protein and TAT-GP5 fusion protein, so as to ensure the biological function of the recombinant protein and solve the problem that the existing technology is difficult to express the full GP5 protein; and a guinea pig immunization inoculation test shows that TAT-GP5 fusion protein can significantly improve the level of humoral immunity and cellular immunity of the body.

The invention discloses a new application of venenum bufonis polypeptide as medicine penetration enhancers, including bufadienolide and the like. An in vitro Franz diffusion cell and an in vivo transdermal experiment test the penetration enhancement effect of the venenum bufonis polypeptide on the bufadienolide. An LC-MS/MS (Liquid Chromatogram-Mass Spectrometry/Mass Spectrometry) method carries out detection to discover that the penetration of six types of main bufadienolide in cavia procellus skins is increased by 36.99-91.13% after the venenum bufonis polypeptide is added. A von Frey filament stimulation method verifies that the venenum bufonis polypeptide can improve the anti-inflammatory and analgesic capability of the bufadienolide. After the venenum bufonis polypeptide is applied, 2% formalin is injected on the right rear foot of the cavia procellus, a test result indicates that the mechanical withdrawal threshold of the right rear foot of the cavia procellus added with the bufadienolide of the venenum bufonis polypeptide is obviously improved, and the mechanical withdrawal threshold is improved by 2-3 times after the formalin is injected for 30min. The venenum bufonis polypeptide can accelerate the penetration of sterene in the skin of the cavia procellus so as to enhance the anti-inflammatory and analgesic effect of the venenum bufonis polypeptide.

The invention provides novel medical application of butylphthalide, i.e. the application of the butylphthalide in the preparation of a medicament for treating the bronchial asthma. The experimental research on the spasmolysis of the butylphthalide on the isolated tracheal smooth muscle of a guinea pig and the influence of the butylphthalide on the incubation period of asthma of the guinea pig shows that the butylphthalide in the concentration range of 3.68*10-6 to 3.68*10-4g/mL has obvious spasmolysis on the tracheal smooth muscle of the guinea pig in the isolated spasticity caused by 5*10-6g/mL of acetylcholine or histamine. On the basis of continuously applying the butylphthalide to the guinea pig which is sensitive for the acetylcholine and the histamine for 10 days, a mixture of the acetylcholine and the histamine is atomized and sucked and the incubation period of asthma is observed. A result shows that 30 mg/kg and 90 mg/kg of butylphthalide has an effect of relieving the tracheospasm of the guinea pig, which is caused by the acetylcholine and the histamine. Therefore, the butylphthalide has a treatment effect on the asthma guinea pig and the treatment effect of the butylphthalide on the asthma guinea pig is related to the effect of inhibiting Ca2+ inner flow and expanded tracheal smooth muscle of the butylphthalide.